RegOS in Practice

Use Cases

How Precoh RegOS has been applied across the clinical AI lifecycle — from pre-submission validation to post-market surveillance.

Where RegOS creates the most impact

Each use case represents a distinct regulatory challenge that RegOS was designed to address — with structured intake, reproducible validation, and tamper-evident outputs.

AI Diagnostics Validation

Pre-submission evaluation of a radiology AI model

1,200-bed Academic Medical Center · Radiology AI · Class II SaMD

A radiology AI developer needed to evaluate their thoracic CT triage model against FDA SaMD requirements before filing. Previous internal reviews had identified some gaps but couldn't quantify them against submission thresholds or produce structured evidence documentation.

RegOS ran a complete five-domain evaluation: data governance, clinical validation, fairness and bias, technical standards, and post-market governance. A fairness warning flagged subgroup performance variance in elderly patients — identified and remediated before submission.

Composite score of 88 / 100 — Approved for regulated use
Fairness gap identified and remediated before FDA filing
Complete sealed evidence package generated for submission
RegOS Pathway
5-domain structured validation → Weighted risk scoring → Regulatory decision → Sealed evidence package
88
Composite score
5
Domains validated
1
Gap remediated pre-filing
Regulatory Sandbox Operations

Standardizing AI evaluation across a national health AI sandbox

National Health AI Oversight Body · Multi-vendor · 50+ submissions

A regulatory sandbox operator was receiving AI submissions in inconsistent formats from multiple developers — each requiring manual review, custom documentation requests, and ad hoc scoring. Decisions were difficult to compare and impossible to audit systematically.

RegOS replaced the ad hoc process with a structured intake pipeline, consistent multi-domain evaluation, and a sealed decision record for every submission. Evaluators moved from document review to structured governance — with every decision traceable to the same rulebook version.

50+ evaluations completed with 100% audit traceability
Review cycle reduced from weeks to structured days
Defensible, comparable decisions across all vendors
RegOS Pathway
Structured intake → Multi-vendor consistent evaluation → Decision trace → Cross-submission comparability
50+
Evaluations run
100%
Fully traceable
FDA & EU
Framework aligned
Real-World Evidence Pipelines

Biopharma oncology label expansion with FDA-grade RWE

Biopharma · Oncology · OMOP CDM · 8.5M patient records

A biopharma company sought to support an oncology label expansion through real-world evidence from a 5-hospital network. The challenge: transforming heterogeneous EHR data into OMOP-standardized, FDA-grade evidence — with a governance trail that could survive regulatory scrutiny.

The Precoh team built an OMOP CDM implementation across all five institutions, standardized 8.5M patient records, designed a computable oncology phenotype, and executed the comparative effectiveness study — delivering a structured evidence package with full data lineage and reproducibility documentation.

8.5M records standardized across 5-hospital OMOP network
FDA-grade evidence package delivered for label expansion
Full data lineage and reproducibility documentation included
RegOS Pathway
Data governance validation → Clinical evidence assessment → Post-market governance framework → Evidence package generation
8.5M
Patient records
5
Hospital sites
FDA
Grade evidence
Post-Market Surveillance

Ongoing governance of a deployed sepsis prediction model

1,200-bed Academic Medical Center · Sepsis AI · 3.2M patient records

A health system had deployed a sepsis prediction model with excellent initial performance — 94.2% sensitivity and 72-hour alert lead time. Eighteen months post-deployment, clinical leadership needed assurance that performance had held across a changing patient population, without the burden of a full re-validation from scratch.

RegOS's post-market governance module ran a structured performance evaluation against 3.2M records, quantified drift across demographic subgroups, and issued an updated evidence package — confirming model validity and projecting the next re-validation trigger point.

Model sensitivity held at 94.2% — performance confirmed
23% reduction in sepsis mortality attributed to early alert
Re-validation trigger projected and documented 18 months out
RegOS Pathway
Post-market governance evaluation → Drift quantification → Updated evidence package → Re-validation scheduling
94.2%
Model sensitivity
72h
Alert lead time
23%
Mortality reduction

See RegOS in action for your use case

Every regulatory challenge is different. Request a conversation and we'll walk through how RegOS applies to your specific context — developer, health system, or regulator.